Campbell & CO Investment Adviser LLC Cuts Stake in Prestige Consumer Healthcare Inc. $PBH

Campbell & CO Investment Adviser LLC lessened its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 68.5% during the 2nd quarter, Holdings Channel reports. The firm owned 6,815 shares of the company’s stock after selling 14,804 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Prestige Consumer Healthcare were worth $544,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in PBH. UMB Bank n.a. lifted its holdings in shares of Prestige Consumer Healthcare by 81.8% in the second quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after buying an additional 144 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Prestige Consumer Healthcare by 312.5% during the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock valued at $26,000 after acquiring an additional 250 shares in the last quarter. Maseco LLP bought a new stake in Prestige Consumer Healthcare in the 2nd quarter valued at $27,000. Geneos Wealth Management Inc. lifted its stake in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 294.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock valued at $48,000 after purchasing an additional 447 shares during the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH opened at $59.97 on Friday. The firm has a market capitalization of $2.88 billion, a PE ratio of 14.08, a PEG ratio of 1.93 and a beta of 0.41. The stock’s fifty day moving average is $62.34 and its 200 day moving average is $72.48. Prestige Consumer Healthcare Inc. has a fifty-two week low of $58.50 and a fifty-two week high of $90.04. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.07 EPS for the quarter, topping the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The company had revenue of $274.11 million during the quarter, compared to analyst estimates of $257.14 million. During the same period in the previous year, the firm earned $1.09 earnings per share. Prestige Consumer Healthcare’s quarterly revenue was down 3.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on PBH shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Jefferies Financial Group cut their target price on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a report on Monday, October 27th. Canaccord Genuity Group reduced their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Oppenheimer lowered their price objective on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research report on Tuesday, October 21st. Finally, Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $85.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.